Ergomed signs up to share costs, profits of Cel-Sci drug

In a novel deal, U.K. CRO Ergomed has hitched up with Cel-Sci ($CVM) for a Phase III trial of its head and neck cancer drug, but instead of just handling the study, Ergomed is putting up $30 million to fund development in exchange for single-digit royalties from the treatment. Neither company disclosed further financial details. More

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.